
PTHS Stock Forecast & Price Target
PTHS Analyst Ratings
Bulls say
Pelthos Therapeutics Inc is experiencing a significant growth trajectory, marked by an impressive 41% sequential increase in prescriptions in October, which exceeded the volume recorded in the entire third quarter. This momentum is backed by an expanding sales force, set to grow from 50 to 64 territory managers targeting approximately 10,000 clinicians, positioning the company for broader market penetration. Furthermore, the upward revision of net revenue projections for 4Q25 to $16.2 million from $4.5 million underscores the strong market demand for its therapeutics and the potential for Pelthos to solidify its revenue base through effective commercial strategies.
Bears say
The negative outlook on Pelthos Therapeutics's stock is primarily attributed to significant risks surrounding its pipeline products, which may fail to deliver statistically significant results in late-stage clinical trials or gain approval from regulatory bodies, thereby diminishing the overall value of the company. Additionally, inadequate reimbursement levels, formulary placement, or slow adoption among healthcare providers may lead to lower-than-expected revenue growth, further impacting projected sales and margins. Furthermore, competitive pressures from existing and emerging products in the market could restrict Pelthos's ability to capture market share and achieve anticipated revenue levels.
This aggregate rating is based on analysts' research of Pelthos Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
PTHS Analyst Forecast & Price Prediction
Start investing in PTHS
Order type
Buy in
Order amount
Est. shares
0 shares